Last reviewed · How we verify
Richard Zimmerman MD — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Fluzone inactivated influenza vaccine | Fluzone inactivated influenza vaccine | marketed | ||||
| FluMist live attenuated influenza vaccine | FluMist live attenuated influenza vaccine | marketed | ||||
| Flucelvax inactivated influenza vaccine | Flucelvax inactivated influenza vaccine | marketed |
Therapeutic area mix
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Richard Zimmerman MD:
- Richard Zimmerman MD pipeline updates — RSS
- Richard Zimmerman MD pipeline updates — Atom
- Richard Zimmerman MD pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Richard Zimmerman MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/richard-zimmerman-md. Accessed 2026-05-17.